The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia.

doi:10.18632/oncotarget.9371

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia.

Oncotarget - 14 Jun 2016

Papakonstantinou Nikos, Ntoufa Stavroula, Chartomatsidou Elisavet, Kotta Konstantia, Agathangelidis Andreas, Giassafaki Lefki, Karamanli Tzeni, Bele Panagiota, Moysiadis Theodoros, Baliakas Panagiotis, Sutton Lesley Ann, Stavroyianni Niki, Anagnostopoulos Achilles, Makris Antonios M, Ghia Paolo, Rosenquist Richard, Stamatopoulos Kostas

Abstract excerpt

The histone methyltransferase EZH2 induces gene repression through trimethylation of histone H3 at lysine 27 (H3K27me3). EZH2 overexpression has been reported in many types of cancer and associated with poor prognosis. Here we investigated the expression and functionality of EZH2 in chronic lymphocytic leukemia (CLL). Aggressive cases with unmutated IGHV genes (U-CLL) displayed significantly higher EZH2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Enhancer of Zeste Homolog 2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Leukemic

Share to Histones

Share to Immunoglobulin Heavy Chains

Share to Immunoglobulin Variable Region

Share to Kaplan-Meier Estimate

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Methylation

Source

Open in PubMed Open full text

Identifiers

PMID: 27191993
DOI: 10.18632/oncotarget.9371
PMCID: PMC5094974

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia.PMID 27191993Read ↗

EZH2 upregulates the PI3K/AKT pathway through IGF1R and MYC in clinically aggressive chronic lymphocytic leukaemiaSemantic proximity Read ↗

EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications.Semantic proximity Read ↗

A key role for EZH2 in epigenetic silencing of HOX genes in mantle cell lymphomaSemantic proximity Read ↗

Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2.Semantic proximity Read ↗

EZH2-associated tumor malignancy: A prominent target for cancer treatment.Semantic proximity Read ↗

Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors.Semantic proximity Read ↗

Overexpression of EZH2 is associated with clinicopathological parameters and poor prognosis in gliomasSemantic proximity Read ↗

EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?Semantic proximity Read ↗

EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphomaSemantic proximity Read ↗

EZH2 is a negative prognostic biomarker associated with immunosuppression in hepatocellular carcinomaSemantic proximity Read ↗

The correlation of EZH2 expression with the progression and prognosis of hepatocellular carcinomaSemantic proximity Read ↗

Multiomics characteristics and immunotherapeutic potential of EZH2 in pan-cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.